

Memorial Sloan Kettering Cancer Center

Strategies to Expedite Activation of Expanded Access Protocols at Memorial Sloan Kettering Cancer Center

Background


- > An NCI-Designated Comprehensive Cancer Center, Memorial Sloan Kettering (MSK) has over 2,000 active clinical trials and expanded access protocols (EAP).
- > EAPs provide access to pre-approval, investigational drugs outside of a clinical trial and patients who rely on them often have no other similar or acceptable therapeutic options available.
- > It is essential to review and activate EAPs efficiently so patients can have access to treatment as soon as possible.
- MSK's Protocol Review Core (PRC) and Protocol Activation Core (PAC) identified roadblocks in reviewing and activating EAPs and established a working group to improve our processes.

Goals

- Create an institutional EAP review and activation workflow
- Decrease EAP Time to IRB Approval (TTIA) [time from primary department submission to IRB approval] and Time to Activation (TTA) [time from primary department submission to activation]

Methods & Solutions

Working group was created, and first task was to streamline institutional definition of EAP: *any protocol with a primary* objective of providing access to a treatment or device with no scientific endpoints.



Xhenete Lekperic, Sara Hanley, MSW, Emily Valentino, MPH, Ann Rodavitch, MA

COR review may be expedited based on their policies regarding investigational radiation use

